Emphysema Treatment Global Market Report 2024
"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Emphysema Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The emphysema treatment market size has grown strongly in recent years. It will grow from $4.96 billion in 2023 to $5.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to smoking epidemic impact, advancements in medications, pulmonary rehabilitation programs, improved diagnostic tools, awareness and education..
The emphysema treatment market size is expected to see strong growth in the next few years. It will grow to $6.85 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to aging population trends, customized treatment approaches, expanded access to therapies, focus on symptom management, collaborative healthcare models.. Major trends in the forecast period include exploration of gene therapies, patient education and empowerment, integration of artificial intelligence (ai), increased accessibility to treatment, long-acting medications development..
Get Free Sample Of This Report-
www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp
Market Segmentation:
The emphysema treatment market covered in this report is segmented -
1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments
2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies
3) By End-User: Clinics, Surgical Centre, Other End-Users
Major Driver - Surging Cases Of Chronic Obstructive Pulmonary Disease (COPD) To Drive Market Growth
The rise in the prevalence of chronic obstructive pulmonary disease (COPD) cases is expected to propel the growth of the emphysema treatment market going forward. Chronic obstructive pulmonary disease (COPD) is a set of disorders that cause airflow obstruction and breathing difficulties, including emphysema and chronic bronchitis. Emphysema therapies are essential in reducing the advancement of Chronic Obstructive Pulmonary Disease (COPD) as they focus on treating symptoms, restoring lung function, and delaying disease progression. For instance, in September 2021, according to the study released by the Forum of International Respiratory Societies, a Switzerland-based respiratory health advocacy organization, an estimated 200 million people have COPD in 2021, with around 3.2 million dying each year, making it the third-leading cause of mortality globally. Therefore, the rise in the prevalence of chronic obstructive pulmonary disease (COPD) cases drives the emphysema treatment market.
Competitive Landscape:
Major companies operating in the emphysema treatment market report are AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Bioxyne Limited, Intrexon Corporation, iCure Pharmaceuticals Inc., Kamada Ltd., Emphasys Medical Inc., Halozyme Therapeutics Inc., Mariposa Health Limited, Uptake Technologies Inc., British Technology Group International , Astellas Pharma Inc., Respinova Ltd, Gala Therapeutics Inc., Pulmatrix Inc., Broncus Medical Inc., Holaira Inc., PneumRx Inc., Spiration Inc., Aeris Therapeutics Inc., CSA Medical Inc., Olympus Corporation
Get Access To The Full Market Report -
www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report
Top Trend - Minimally Invasive Procedures Transforming The Market
Major companies operating in the emphysema market are developing minimally invasive procedures for emphysema patients to gain a competitive edge in the market. Minimally invasive procedures refer to medical interventions or surgical techniques that are performed with minimal disruption to the body's normal structures. For instance, in January 2022, Adena Health System, a US-based healthcare company, launched the Zephyr Valve surgery. It is a minimally invasive procedure that offers an alternative to conventional lung volume reduction surgery for individuals experiencing lung hyperinflation, a common issue in emphysema and COPD. This innovative approach involves placing small, one-way Zephyr Valves in the airways of the lungs via a bronchoscope. These valves facilitate the release of trapped air, preventing further accumulation, and allowing healthier lung areas to expand, thereby improving breathing.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Emphysema Treatment Market Characteristics
3. Emphysema Treatment Market Trends And Strategies
4. Emphysema Treatment Market - Macro Economic Scenario
5. Emphysema Treatment Market Size And Growth
…..
27. Emphysema Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: in.linkedin.com/company/the-business-research-company
Twitter: twitter.com/tbrc_info
Facebook: www.facebook.com/TheBusinessResearchCompany
YouTube: www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: blog.tbrc.info/
Healthcare Blog: healthcareresearchreports.com/
Global Market Model: www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
This release was published on openPR.
